{"id":11233,"date":"2025-12-17T22:21:06","date_gmt":"2025-12-18T06:21:06","guid":{"rendered":"https:\/\/dhs.lacounty.gov\/harbor-ucla-medical-center\/?page_id=11233"},"modified":"2026-03-05T16:11:05","modified_gmt":"2026-03-06T00:11:05","slug":"faculty","status":"publish","type":"page","link":"https:\/\/dhs.lacounty.gov\/harbor-ucla-medical-center\/gme\/infectious-diseases\/faculty\/","title":{"rendered":"ID & HIV Core Clinical Faculty"},"content":{"rendered":"

[vc_row][vc_column width=”1\/2″][vc_single_image image=”11258″ img_size=”full” css=””][vc_column_text css=””]Brian Chow, M.D.
\nDivision of HIV Medicine[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766038799558-8b53e906-3ab6″][vc_column_text css=””]Brian Chow, MD, is an attending physician in the Division of HIV Medicine and Director of the Beall Positive Care Clinic.\u00a0 Prior to joining Harbor-UCLA, he was an ID and Transplant ID fellowship program director.<\/p>\n

Dr. Chow graduated with a B.E., summa cum laude, with honors in biomedical engineering from Vanderbilt University, and an M.D. from Case Western Reserve
\nUniversity. He completed internal medicine-pediatrics residency at Case Western Reserve University (University Hospitals Cleveland Medical Center\/Rainbow Babies and Children\u2019s Hospital) in the Global Health Track and served as Chief Resident. He completed fellowship training in combined adult\/pediatric infectious diseases at Brown University, where he was awarded a Thrasher Research Foundation Early Career Award. He has worked on research and quality improvement projects on vaccines and clinical trials for vaccines and COVID-19 therapies. He continues to work on clinical trials which advance novel therapeutics. He is passionate about linking and retaining people living with HIV in care and preventing HIV infection.[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][vc_column width=”1\/2″][vc_single_image image=”11257″ img_size=”full” css=””][vc_column_text css=””]Katya Corado, M.D.
\nDivision of HIV Medicine[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039054870-60d63b9e-e8aa”][vc_column_text css=””]Dr. Corado joined the Division of HIV Medicine at Harbor-UCLA Medical Center in 2012. She is a graduate of the David Geffen School of Medicine at UCLA, completed her internal medicine residency at Harbor-UCLA Medical Center and her infectious diseases fellowship at the University of New Mexico School of Medicine. Dr. Corado spends half her time working within the Ambulatory Care Network, providing primary medical care to HIV patients at the Tom Kay Clinic as well as working to unify the seven HIV clinics across Department of Health Services (DHS). Her work at Harbor-UCLA includes teaching and research. Her research includes clinical trials focusing on adherence to pre-exposure prophylaxis (PrEP) in HIV, ongoing QI project within DHS about PREP, and since the COVID pandemic, has been involved in ACTIV-2, studying new medications for the outpatient treatment of COVID-19. She has partnered with NIH to provide education to the Spanish-speaking community about vaccines and has participated in numerous outreach events.[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][vc_single_image image=”11256″ img_size=”full” css=””][vc_column_text css=””]Eric Daar, M.D.
\nChief, Division of HIV Medicine[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039088674-089cc102-81ab”][vc_column_text css=””]Dr. Eric S. Daar is Chief of the Division of HIV Medicine and member of the Division of Infectious Diseases at Harbor-UCLA Medical Center, Professor of Medicine at the David Geffen School of Medicine at UCLA and Investigator at the Lundquist Institute. He has devoted his career to treating patients with HIV infection and studying the pathogenesis of acute and chronic infection, as well as further defining the optimal management of HIV infection and its complications.\u00a0 Following his undergraduate education at UCLA, he attended Georgetown University Medical School and did both his Internal Medicine residency and Infectious Diseases fellowship at Cedars-Sinai Medical Center. After being Chief of Infectious Diseases at Cedars-Sinai he relocated his clinical and research activities to Harbor-UCLA Medical Center in 2001. His most recent research focuses upon HIV immuno- and neuro-pathogenesis, along with optimizing therapy for HIV. Additional research is in the area of HIV testing, linkage and retention into care and prevention. Since the beginning of the COVID-19 pandemic he has been actively involved in clinical research related to the management of disease, including being Vice Chair of the ACTIV-2 protocol, a public-private venture to develop novel treatments for non-hospitalized patients with mild-to-moderate COVID-19.\u00a0 He is lead investigator for the Lundquist Institute at Harbor-UCLA Clinical Research Site of the AIDS Clinical Trials Group, as well as being steadily funded by numerous NIH and Industry grants.\u00a0 He has published more than 500 peer-reviewed manuscripts and abstracts and serves on the Editorial Board and\/or as a reviewer for many high profile scientific journals. In addition, he currently serves as a Panel member on the Department of Health and Human Services Adult and Adolescent HIV Treatment Guidelines and on the NIH COVID-19 Treatment Guidelines.<\/p>\n

Publications<\/a><\/strong>[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][vc_column width=”1\/2″][vc_single_image image=”11255″ img_size=”full” css=””][vc_column_text css=””]Stephen Judge, M.D.
\nDivision Infectious Diseases[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039088848-a158d7b2-72c3″][vc_column_text css=””]<\/p>\n

\n

Coming soon<\/p>\n<\/div>\n

[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][vc_single_image image=”11254″ img_size=”full” css=””][vc_column_text css=””]Caroline Koan, M.D.
\nDivision of HIV Medicine[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039088017-31091a80-059b”][vc_column_text css=””]Coming soon[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][vc_column width=”1\/2″][vc_single_image image=”11253″ img_size=”full” css=””][vc_column_text css=””]Timothy Hatlen, M.D.
\nDivision of HIV Medicine. Program Director, ID Fellowship[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039088185-f5ad6c6f-f745″][vc_column_text css=””]Dr. Hatlen joined the Division of HIV Medicine in 2019.\u00a0 Since 2022, he serves as the Program Director of the Infectious Diseases Fellowship and is the Hepatitis C subspecialty clinic director. He received his medical degree from the University of Washington School of Medicine and completed Internal Medicine internship and residency in Spokane, Washington.\u00a0 His training in Infectious Diseases and HIV was completed at Harbor-UCLA.<\/p>\n

Research passions include HIV related health outcomes and novel treatment strategies for na\u00efve or highly resistant populations. Additionally, he has been involved in numerous SARS-CoV2 clinical research studies spanning prevention from vaccines and monoclonal antibodies to treatment and long term outcomes.\u00a0 He is a primary investigator for multiple inpatient COVID-19, HIV, and Hepatitis C studies.\u00a0 One of his true passions is in medical education for resident and fellows in Infectious Diseases and HIV.<\/p>\n

Publications<\/a>[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][vc_single_image image=”11252″ img_size=”full” css=””][vc_column_text css=””]Pam Lee, M.D.
\nAssociate Chief, Division of Infectious Diseases[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039087432-f07dfc47-bb6a”][vc_column_text css=””]Dr. Pam Lee joined the Division of Infectious Diseases at Harbor-UCLA in 2022. Originally from Los Angeles, she received her MD at the University of Cincinnati in 2015 then joined the Los Angeles Department of Health Services immediately out of medical school, when she entered internal medicine residency at LA County \u2013 USC. She completed\u00a0infectious disease fellowship at Harbor-UCLA, and following this, she joined DHS\u2019s Ambulatory Care Network as an infectious disease specialist. There, she functioned as their lead physician for infection control and helped develop and lead outpatient COVID-19 treatment programs across LA county. She also completed a medical education fellowship at UCLA from 2020 \u2013 2021. Her interests include antibiotic and diagnostic stewardship, particularly in the outpatient setting, infection prevention and control, and healthcare decarbonization. She aspires to be a clinician-educator, advocate for underserved populations, and to provide high-quality medical care for the Los Angeles community she calls home.<\/p>\n

Publications<\/a><\/strong>[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][vc_column width=”1\/2″][vc_single_image image=”11251″ img_size=”full” css=””][vc_column_text css=””]Raul Macias Gil, M.D.
\nDivision of Infectious Diseases. APD, ID Fellowship[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039087554-225bd5ce-a543″][vc_column_text css=””]Dr. Raul Macias Gil joined the Division of Infectious Diseases at Harbor-UCLA in 2021. He received his medical degree from the Autonomous University of San Luis Potosi, Mexico. He completed his Internal Medicine Residency at Highland Hospital in Oakland, CA, and his Infectious Disease Fellowship at the Alpert Medical School of Brown University.<\/p>\n

His clinical interests include general infectious diseases, HIV medicine, infection control, antimicrobial stewardship, medical education, and LGBTQ+ health. His current research focuses on healthcare disparities and the impact of the COVID-19 pandemic on vulnerable populations, particularly in the Hispanic\/Latinx community.<\/p>\n

Dr. Macias Gil is a founding member of the Infectious Diseases Society of America (IDSA)\u2019s Inclusion, Diversity, Access & Equity Committee (IDA&E).<\/p>\n

Twitter handle: @RMGmdID<\/p>\n

Publications<\/a>[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][vc_single_image image=”11250″ img_size=”full” css=””][vc_column_text css=””]Loren G. Miller, M.D., M.P.H.
\nChief, Division of Infectious Diseases[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039086622-859c5945-5613″][vc_column_text css=””]Dr. Miller earned his undergraduate degree from UC Berkeley, and went on to attain his medical degree from Columbia University College of Physicians and Surgeons.\u00a0 After completing residency at Harbor-UCLA Medical Center, he completed fellowships in Infectious Diseases at the UCLA Multicampus\u00a0 Program In Infectious Disease and Microbial Pathogensis, and at the UCLA\/VA Multicampus Fellowship in Health Services Research. He also received a Master\u2019s Degree in Public Health from UCLA. He has extensive experience in Infection Control and served as the Director of Infection Prevention and Control at Harbor-UCLA Medical Center from 2007 to 2015. He now is the Chief of the Division of Infectious Diseases and is also the Director of the Harbor-UCLA Infectious Diseases Clinical Outcomes Research Unit (ID-CORE), a burgeoning research group specializing in data collection, management and analysis of important infectious diseases. \u00a0 Dr. Miller leads epidemiologic, health services, and clinical research investigations focusing on community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections and skin infections, urinary tract infections, and hepatitis, among other topics. \u00a0He has been the Principal Investigator or Co-Investigator on many investigations and clinical trials sponsored by the National Institutes of Health (NIH), the U.S. Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and Quality (AHRQ), and other governmental research agencies. Dr. Miller has been recognized through many awards, including the NIH (NIAID) Mentored Patient-Oriented Research Career Development Award (K23), the Harbor-UCLA Collegium Award for Research Instrument, the Richard Weitzman Memorial Research Award for Outstanding Young Investigator, and in 2011, the \u201cMan of the Year\u201d Award from the MRSA Survivor\u2019s Network. Dr. Miller has authored over 100 manuscripts in peer-reviewed journals and chapters on a broad range of topics in infectious diseases and internal medicine.<\/p>\n

Publications<\/a><\/strong>[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][vc_column width=”1\/2″][vc_single_image image=”11249″ img_size=”full” css=””][vc_column_text css=””]Mallory D. Witt, M.D.
\nDivision of HIV Medicine[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039086734-bd59c6af-17a0″][vc_column_text css=””]Dr. Mallory D. Witt attended medical school at the Stanford University School of Medicine, completed internship and residency at UCSF, and was an Infectious Diseases fellow at Harbor-UCLA.\u00a0 She is Professor of Clinical Medicine at the David Geffen School of Medicine at UCLA, Associate Chief, in the Division of HIV Medicine, and serves as Director of the HIV Clinic (Positive Care Clinic) at Harbor-UCLA Medical Center.\u00a0 She also serves as Vice Chair of the Bioethics Committee at Harbor-UCLA.\u00a0 In her role as the HIV Clinic Director, Dr. Witt oversees the care of approximately 850 HIV+ patients, with over 400 clinic visits per month, thanks to the help of a strong team of ID fellows, Nurse Practitioners, social workers, medical case workers, a dietician, and a group of highly skilled faculty.\u00a0 Dr. Witt has served as the site Principal Investigator for a wide variety of federal and state funded studies of HIV and its complications.\u00a0 She is a Principle Investigator for the combined Multicenter AIDS Cohort Study\/Women\u2019s Interagency Cohort Study, a longstanding study of the natural history of HIV infection and its complications, viral hepatitis and other co-infections, and complications of HIV therapies, and also serves as a co-investigator in the AIDS Clinical Trials Group (ACTG).\u00a0 Her research interests include\u00a0 evaluation of cardiovascular complications of HIV and its therapies, as well as hepatic, neurologic, and renal complications of HIV disease.<\/p>\n

Publications<\/a><\/strong>[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator css=””][vc_column_text css=””]<\/p>\n

Distinguished Clinical & Research Faculty<\/strong><\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][vc_single_image image=”11248″ img_size=”full” css=””][vc_column_text css=””]John E. Edwards, Jr., M.D.
\nProfessor of Medicine Emeritus[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039085492-0cf788f0-6c22″][vc_column_text css=””]Dr. Edwards is Emeritus Distinguished Professor of Medicine, David Geffen School of Medicine at UCLA, and Emeritus Chief, Division of Infectious Disease at Harbor-UCLA Medical Center. \u00a0He has devoted his career to studying the pathogenesis and therapy of fungal infectious diseases, principally caused by\u00a0Candida albicans. Following his education at\u00a0Pomona\u00a0College, the UC Irvine College of Medicine, and ensuing post-doctoral training at\u00a0Harbor-UCLA\u00a0Medical\u00a0Center, he has been committed to research on both cellular and molecular mechanisms of fungal pathogenesis for over 40 years.\u00a0 Recently, Dr. Edwards and his group have focused their research efforts on determining specific proteins that mediate\u00a0Candida\u00a0interactions with human cells.\u00a0 The goals of these efforts are to understand interactions of\u00a0C. albicans,\u00a0endothelial cells, and immune responses.\u00a0 These interactions determine how\u00a0Candida\u00a0exploits the vascular compartment to invade deeper organ tissues. He and colleagues have characterized ALS-type adhesions of\u00a0C. albicans\u00a0using a combination of genetics and\u00a0in vivo\u00a0models.\u00a0 These advances revealed specific proteins that could be used as vaccine candidates.\u00a0 Dr. Edwards and his team are currently optimizing the safety and efficacy of such targets as new vaccines. With his work he hopes to dramatically advance the development of new anti-fungal agents and immunotherapies to prevent and treat life-threatening infections.<\/p>\n

Publications<\/a><\/strong>
\n[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][vc_column width=”1\/2″][vc_single_image image=”11247″ img_size=”full” css=””][vc_column_text css=””]Scott Filler, M.D.
\nAcademic Chief of Research[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039085654-919fe333-6fdc”][vc_column_text css=””]Dr. Filler is Professor of Medicine, David Geffen School of Medicine, and Chief, Division of Infectious Diseases, Harbor-UCLA Medical Center. He completed his undergraduate education at\u00a0Dartmouth\u00a0College\u00a0in\u00a0Hanover,\u00a0New Hampshire, where he graduated\u00a0Magna cum Laude.\u00a0 He then received his medical degree from the UCLA School of Medicine, and performed an internship and residency in internal medicine before completing a fellowship in infectious diseases at\u00a0Harbor-UCLA\u00a0Medical\u00a0Center. \u00a0His research focuses on the mechanisms by which pathogens including\u00a0Candida albicans\u00a0and\u00a0Aspergillus fumigatus\u00a0invade and damage human cells, causing life-threatening infections. \u00a0Dr. Filler and his team discovered the first two fungal invasins.\u00a0 He is co-founder and scientific advisory board member of NovaDigm Therapeutics, Inc., which is developing vaccines that address the increasing challenge of drug-resistant fungal and bacterial infections.\u00a0 A widely sought lecturer at professional conferences around the world, Dr. Filler has authored or co-authored more than 100 peer-reviewed papers, book chapters and reviews. He is inventor on 3\u00a0U.S.\u00a0patents of pharmaceutical compositions to vaccinate against disseminated candidiasis. \u00a0Dr. Filler is the Program Director for the Infectious Diseases Fellowship at Harbor-UCLA.<\/p>\n

Publications<\/a><\/strong>[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator css=””][vc_column_text css=””]<\/p>\n

Microbiology<\/strong><\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][vc_single_image image=”11246″ img_size=”full” css=””][vc_column_text css=””]Holly Huse, Ph.D., D(ABMM), M(ASCP), PMH
\nDirector of Microbiology. Department of Pathology[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039618498-f278ec59-0351″][vc_column_text css=””]Dr. Holly Huse completed her Ph.D. at the University of Texas at Austin, where she studied chronic pulmonary infections in individuals with cystic fibrosis. Following her Ph.D., she completed an academic post-doctoral fellowship at the University of Washington studying genetic mechanisms of desiccation tolerance in\u00a0Acinetobacter baumannii<\/em>. During her time at the University of Washington, she gained a passion for clinical microbiology and went on to complete a CPEP Medical Microbiology and Public Health Laboratory fellowship at the University of California Los Angeles. Dr. Huse is certified by the American Board of Medical Microbiologists (ABMM), and she is currently the Director of Microbiology at Harbor-UCLA in Torrance, CA. Her research interests include evaluating the performance of antimicrobial susceptibility testing methods for pulmonary pathogens associated with cystic fibrosis, including\u00a0Pseudomonas aeruginosa<\/em>\u00a0and the\u00a0Burkholderia cepacia<\/em>\u00a0complex.<\/p>\n

Publications<\/a><\/strong>[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][vc_column width=”1\/2″][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator css=””][vc_column_text css=””]<\/p>\n

Pharmacy: Antibiotic Stewardship<\/strong><\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][vc_single_image image=”11245″ img_size=”full” css=””][vc_column_text css=””]Amy Kang, Pharm.D.
\nChair, Antibiotic Stewardship Team[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039634355-57d563d9-9f45″][vc_column_text css=””]Coming soon[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][vc_column width=”1\/2″][vc_single_image image=”11244″ img_size=”full” css=””][vc_column_text css=””]Gary Fong, Pharm.D.
\nAntibiotic Stewardship Team[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039634647-37695d0f-6610″][vc_column_text css=””]Coming Soon[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][vc_single_image image=”11243″ img_size=”full” css=””][vc_column_text css=””]Grace Lee, Pharm. D.
\nAntibiotic Stewardship Team[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039633676-cf03c96a-02b0″][vc_column_text css=””]Coming Soon[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][vc_column width=”1\/2″][vc_single_image image=”11242″ img_size=”full” css=””][vc_column_text css=””]Sean Oh, Pharm. D.
\nAntibiotic Stewardship Team[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039633941-bc2b0be6-45fa”][vc_column_text css=””]Coming Soon[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator css=””][vc_column_text css=””]<\/p>\n

Infectious Diseases Core Research Faculty<\/strong><\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][vc_single_image image=”11241″ img_size=”full” css=””][vc_column_text css=””]Liana Chan, Ph.D.
\nAdjunct Assistant Professor Division of Molecular Medicine[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039631655-1b820b57-017b”][vc_column_text css=””]Dr. Chan is an Adjunct Assistant Professor in the Division of Molecular Medicine at Harbor-UCLA Medical Center. She earned her Ph.D. in Infectious Diseases & Immunity from the University of California, Berkeley and trained under Dr. Henry F. \u201cChip\u201d Chambers at the University of California, San Francisco. There, she studied novel mechanisms of antibiotic resistance in methicillin-resistant Staphylococcus aureus (MRSA) with funding from the Soroptimist Foundation and UC Berkeley. In 2014, she joined the lab of Dr. Michael Yeaman at Harbor-UCLA and focused on understanding protective immune determinants against recurrent MRSA infections. To fund this research, she was awarded a Postdoctoral Fellowship Grant from the American Heart Association. In 2019, she joined the faculty at the David Geffen School of Medicine at UCLA as an Adjunct Assistant Professor. Simultaneously, she also joined the Lundquist Institute at Harbor UCLA Medical Center as an investigator. In this new position, her research is focused on epigenetic mechanisms of innate immune memory against MRSA. She has published 19 peer-reviewed research papers, including 6 in the Proceedings of the National Academy of Sciences of the United States of America (PNAS). To fund this research, Dr. Chan received a Career Develop Award from the UCLA Clinical and Translational Science Institute.<\/p>\n

Click\u00a0here<\/a>\u00a0for a link to Dr. Chan\u2019s publications<\/strong><\/p>\n

[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][vc_column width=”1\/2″][vc_single_image image=”11240″ img_size=”full” css=””][vc_column_text css=””]Ashraf S. Ibrahim, Ph.D.
\nProfessor of Medicine[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039631883-20499076-8fc9″][vc_column_text css=””]<\/p>\n

Dr. Ibrahim is a Professor at David Geffen School of Medicine at UCLA and a Senior Investigator, Director of the Graduate Studies Program and Vice-Chair of BOD of The Lundquist Institute for Biomedical Innovations at Harbor-UCLA Medical Center (Lundquist Institute). He received his Ph.D degree in Microbial Physiology from Loughborough University of Technology, UK.<\/p>\n

Dr. Ibrahim completed his Postdoctoral training in Infectious Diseases at The Lundquist Institute. His research focuses on molecular pathogenesis, host-pathogen interactions, and models of infections.\u00a0 His laboratory is internationally recognized as a leading group in mucormycosis research in which they established genetic manipulation of\u00a0Rhizopus<\/i>\u00a0(the most common cause of infection), developed clinically relevant animal models of infection and pioneered the discovery of novel therapies in treating the disease. Currently, his laboratory is leading the effort in developing antibody-based therapy and rapid diagnostics for this lethal fungal infection through STTR\/SBIR funding mechanisms to Vitalex Biosciences, a company that he founded.<\/p>\n

Dr. Ibrahim is also a leading figure in developing a vaccine that targets healthcare-related infections caused by multidrug-resistant such as\u00a0Candida<\/i>\u00a0(including the emerging multidrug resistant\u00a0C. auris<\/i>)\u00a0Acinetobacter<\/i>\u00a0and\u00a0Klebsiella pneumonia<\/i>. For his efforts in this field and in collaboration with NovaDigm Therapeutics (a spinoff company that he cofounded for vaccine development), Dr. Ibrahim was recently awarded a $ 5.5 million R01grant to manufacture a dual antigen vaccine.<\/p>\n

The Ibrahim\u2019s laboratory is instrumental in the preclinical development programs of several antibiotics\/small molecules advanced by industry (e.g. Merck, Astellas Pharma, Gilead, Amplyx Pharmaceuticals, Cidara and A6 Pharmaceuticals, etc.). These efforts range from development of antifungal agents, to targeting multidrug-resistant Gram-negative sepsis.<\/p>\n

Dr. Ibrahim currently holds several NIH and industry-sponsored projects and has received over $27 M in funding for his research.\u00a0 He coauthored >170 peer-reviewed research papers, review articles and book chapters. He is an elected member of the American Academy of Microbiology and a receiver of several prestigious award for excellence in research. For the last 10 years, Dr. Ibrahim served on numerous NIH study sections as an Ad Hoc reviewer, and currently is a member of the Drug Discovery and Mechanisms of Antimicrobial Resistance (DDR) study section.<\/p>\n

Publications<\/a><\/strong><\/p>\n

[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][vc_single_image image=”11239″ img_size=”full” css=””][vc_column_text css=””]Nagendra Mishra, Ph.D.
\nAssociate Professor of Medicine[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039631053-4b52d7fa-6d11″][vc_column_text css=””]Dr. Mishra is Associate Professor of Medicine at UCLA David Geffen School of Medicine. He earned his PhD in biochemistry from the University of Allahabad in India. In addition, he completed his post-doctoral training in infectious diseases at The Lundquist Institute at Harbor UCLA Medical Center. His lab studies the adaptations associated with membrane lipids of Candida, Staphylococci, Enterococci and Streptococci that confer resistance to certain antibiotics in vitro and in vivo. He also discovered the significance of Staphylococcal carotenoid augmented membrane fluidity\/rigidity and its implications in resistance to host defense peptides and in vivo virulence in an endocarditis model. Further understanding microbial adaptation to the host in the setting of anti-infective agents aims to open new doors to anti-infective strategies addressing the current challenge of conventional antibiotic resistance. Dr. Mishra has been reviewer of many prestigious scientific journals, academic editor of reputed journals and\u00a0\u00a0 research grants of international grant agencies. He has an excellent funding records of getting pharmaceutical grants and Co-Investigators on NIH R01 grants. Dr. Mishra was honored by the American Society of Microbiology with a 2015 ICAAC (Interscience Conference of Antimicrobial Agents and Chemotherapy) Young Investigator Award.The award recognizes early career scientists for research excellence and potential in microbiology and infectious disease. He has contributed more than 50 research articles, reviews and chapters in peer-reviewed journals.<\/p>\n

Publications<\/a><\/strong><\/p>\n

[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][vc_column width=”1\/2″][vc_single_image image=”11238″ img_size=”full” css=””][vc_column_text css=””]Shakti Singh, Ph.D.
\nAssistant Professor-In-Residence[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766039631272-b501768d-4f7c”][vc_column_text css=””]Coming soon[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/2″][vc_single_image image=”11237″ img_size=”full” css=””][vc_column_text css=””]Marc Swidergall, Ph.D.
\nAssistant Professor-in-Residence[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766040048067-be954490-af72″][vc_column_text css=””]Dr. Swidergall is Assistant Professor at the David Geffen School of Medicine at UCLA, and Investigator at The Lundquist Institute at Harbor-UCLA Medical Center. He earned undergraduate degrees in Biology and Microbiology, and a Ph.D. in Molecular Mycology in 2015 from the Heinrich-Heine-University in Dusseldorf, Germany. Dr. Swidergall completed a fellowship in Medical Mycology at the Harbor-UCLA Medical Center. His research advances the understanding of immune responses during invasive and mucosal fungal infections. Dr. Swidergall\u2019s goal is to develop a detailed mechanistic understanding of the molecular and cellular basis of innate and adaptive immunity against\u00a0fungal pathogens\u00a0with an aim to devise novel strategies to supplement the current antifungal drug treatment. He has co-authored over 20 peer-reviewed research papers, book chapters and review articles and serves as reviewer for peer-reviewed journals. He received a Young Investigator award from the German Society for Hygiene and Microbiology in 2014, and was awarded a prestigious Career Development Grant from the National Institutes of Health (NIH).<\/p>\n

Publications<\/a><\/strong>[\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][vc_column width=”1\/2″][vc_single_image image=”11236″ img_size=”full” css=””][vc_column_text css=””]Priya Uppuluri, Ph.D.
\nAssistant Professor[\/vc_column_text][vc_tta_accordion active_section=”0″ collapsible_all=”true”][vc_tta_section title=”Bio” tab_id=”1766040048522-46b33734-9c6c”][vc_column_text css=””]<\/p>\n

Dr. Uppuluri\u2019s lab focuses on the molecular basis underlying biofilm growth and dispersal in the human fungal pathogen Candida albicans. Dr. Uppuluri\u2019s lab has reported that biofilm dispersed cells have properties more invasive and virulent than any other growth phases of C. albicans, including biofilms. Understanding the molecular basis underlying biofilm dispersal, and identification of genetic targets on the fungus to abrogate the process of dispersion is the focus of the laboratory.<\/div>\n
\n
<\/div>\n<\/div>\n
\n

Education<\/h3>\n